Business Standard

Monday, December 23, 2024 | 12:01 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

US respiratory portfolio to drive medium term sales growth for Cipla

In the domestic market, growth is expected to come from Covid-related drugs

Cipla, Cipla logo, Cipla headquarters
Premium

An employee works at the reception area of Cipla at its headquarters in Mumbai. Photo: Reuters

Ram Prasad Sahu Mumbai
Near-term gains from the increased demand for Covid-related drugs, medium-term traction from the chronics portfolio, and fresh launches in the US are expected to sustain the revenue and earnings growth trajectory for Cipla. These triggers, coupled with a preference for pharma and defensive stocks amid the second wave of Covid in India, saw Cipla gain nearly 25 per cent over the past month.

The immediate trigger is the rising demand for anti-viral and other formulations used for the treatment of coronavirus infection. The company, which accounts for about half the Remdesivir (anti-viral) market in India, is doubling its production and is

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in